INDAPTUS THERAPEUTICS INC. - COMMON STOCK

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

13 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

08 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

22 Nov 2024 08:36:14 By Nasdaq GlobeNewswire

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

11 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

23 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

22 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire